Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Growth Hormone Releasing Peptide-2
GHRP-2 (pralmorelin) is a synthetic hexapeptide ghrelin receptor agonist that stimulates pituitary growth hormone release. It is approved in Japan (Kaken Pharmaceutical, 2004) as a single-dose diagnostic agent for GH deficiency, but is NOT FDA-approved in the US and is research-only. Unlike ipamorelin, GHRP-2 is non-selective and modestly raises ACTH, cortisol, and prolactin.
GHRP-2 binds the ghrelin/GHS-R1a receptor on pituitary somatotrophs and in the hypothalamus, triggering Gq-coupled calcium signaling and pulsatile GH release while also suppressing somatostatin tone. At therapeutic and supratherapeutic doses it produces measurable rises in ACTH, cortisol, and prolactin (less than GHRP-6 or hexarelin, but more than ipamorelin) and stimulates appetite through ghrelin-pathway activation.
Pralmorelin is approved in Japan as a diagnostic GH-stimulation test (100 mcg IV; peak GH <15 mcg/L cut-off validated against the insulin tolerance test by Chihara et al., 2007). Arvat et al. (1997) showed GHRP-2 raises GH, prolactin, ACTH, and cortisol in healthy men (comparable to hexarelin). Laferrère et al. (2005) demonstrated GHRP-2 infusion increases food intake in healthy men. There are no FDA-approved indications; anti-aging and performance use is unvalidated grey-market use.
Typical Dose
100–300 mcg (grey-market); 100 mcg IV single dose (Japan diagnostic)
Frequency
1–3 times daily (grey-market)
Route
SubQ or IV
Notes
Research-use only in the US. Grey-market protocols use SubQ on an empty stomach, often stacked with a GHRH analog (CJC-1295/sermorelin) for synergistic GH release. No clinically validated chronic-use dose for anti-aging or body composition.
Aggregated from 10 lab-verified Certificates of Analysis uploaded directly by labs. Purity averages exclude values outside [50%, 100%] to filter unit-misreads.
COAs
10
Verified labs
0
Avg purity
99.36%
±0.53%
Endotoxin tested
40%
This platform provides informational tools only, not medical advice. This information is for educational purposes only. Consult a licensed provider.